Stay updated on Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Sign up to get notified when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page now displays the completed study record for the tislelizumab-versus-sorafenib trial, including its design, outcomes, locations, publications, and study documents, instead of a 403 error page.
    Difference
    100%
    Check dated 2026-11-08T12:30:11.000Z thumbnail image
  2. Check
    11 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-01T13:14:06.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    A site-wide banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to updates and FAQs.
    Difference
    1%
    Check dated 2026-10-25T13:07:11.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T12:34:28.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision label updates from v3.7.0 to v3.7.1. The page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-11T13:19:24.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The page now shows a 403 Forbidden error, replacing the study content and navigation with a standard error page. This blocks access to the study details.
    Difference
    19%
    Check dated 2026-09-20T20:34:17.000Z thumbnail image

Stay in the know with updates to Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Tislelizumab vs Sorafenib in Unresectable HCC Clinical Trial page.